Notícias e Atividades da BlueRock Therapeutics
Presença
Sede: Canadá
Bayer é uma das ...
- Dax 40;
- Forbes Global 2000 (#618);
- Fortune 500 Europe (#69);
- Global Fortune 500 (#301);
- Stoxx 600;
- TOB Iconic 10,000.
Bayer é uma empresa listada sob o símbolo BAYN (DE).
Bayer tem presença direta em 20 países.Bayer possui 39 subsidiárias incluindo AskBio, Bayer ANZ e Bayer APAC.
Eles estão dentro:
- Farmacêutica68%
- Biotecnologia15%
- Outro18%
Fusão, aquisição e financiamento envolvendo Bayer.
- Bayer has announced the acquisition of Perfuse Therapeutics (publicado em 6 de maio de 2026).
Executivos
Veja o organograma con seus 38 executivos principais
Biografias mais buscadas da BlueRock Therapeutics
- Seth Ettenberg, Director, President and Chief Executive Officer
- Doug Kerr, Director
- Juergen Eckardt, Director
Recentes movimentos de executivos em BlueRock Therapeutics
- Stefan Irion, Chief Scientific Officer, deixou a Companhia (Notícia publicada em 4 de maio de 2026).
Recentes movimentos de executivos em Bayer
- Judith Hartmann ingressará na Companhia como Chief Financial Officer em 1 de mai. de 2026 (Notícia publicada em 8 de novembro de 2025).
Criar um alerta
para seguir os movimentos de executivos da BlueRock Therapeutics.
Biotecnologia
Bayer possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).
Popular M&A news in Biotecnologia
- IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
- NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado em 1 de junho de 2026)..
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de BlueRock Therapeutics
- News - BlueRock Therapeutics LP
- BlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell TherapyBlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell Therapy
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Diseas
- BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced
- Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine - Engineered Cell TherapySenti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Th
- BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases - Engineered Cell TherapyBlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis The
- BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
- BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
- View more press releases Close
Redes sociais sobre BlueRock Therapeutics
- BlueRock Therapeutics na Wikipedia, Google News e Yahoo Finance
- BlueRock Therapeutics na LinkedIn, X (Twitter) e YouTube
